KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum
–New data show effectiveness of sebetralstat in reducing anxiety during attacks; supports need for oral on-demand option to treat attacks earlier and more often–
–Patient perspectives spotlight the prevalence of anxiety when faced with administering injectable on-demand therapies–
KONFIDENT was the first randomized controlled trial to assess the impact of an on-demand treatment on anxiety associated with HAE attacks. This prespecified exploratoryanalysis was presented by Dr.
“The data presented at the
Additional poster presentations at the
-
Anxiety Associated with Parenteral On-Demand Treatment for Hereditary Angioedema Attacks:
Riccardo Senter ,Azienda Ospedaliera , Università degli Studi diPadova ,Padova, Italy - A substantial proportion of survey respondents experienced moderate to extreme anxiety due to anticipated use of on-demand treatment, particularly adolescents and those previously diagnosed with anxiety.
- Reasons for anxiety were most commonly related to treatment effectiveness, administration burden/side effects, and cost/access.
- Effective alternatives to current parenteral on-demand treatments are needed to address treatment-related anxiety associated with HAE attacks.
-
The Hereditary Angioedema (HAE) Attack Journey: A Conceptual Model of Patient Anxiety and On-Demand Treatment
Burden During an HAE Attack:Douglas Jones ,Metrodora Institute ,Salt Lake City, Utah - The survey highlighted that people living with HAE experience anxiety when anticipating parenteral on-demand treatment.
- People with HAE often delay administering on-demand treatment with longer treatment delays reported by those feeling moderately to extremely anxious.
- Participants expressed that anxiety decreased once they began to recover from their attacks.
-
Impact of Delayed Treatment of Hereditary Angioedema Attacks on Quality of Life and Ability to Work:
Patrick Yong ,Frimley Health NHS Foundation Trust , Frimley,United Kingdom - Nearly all participants waited an hour or longer to treat their attacks and reported quality of life and work productivity were worse.
- Findings highlight the need for more education on treating at the earliest recognition of an attack and addressing barriers that contribute to treatment delays.
-
Impact of Hereditary Angioedema Attacks on Quality of Life and Ability to Work Among
UK Patients Receiving Long-term Prophylaxis or On-demand Treatment Only:Patrick Yong ,Frimley Health NHS Foundation Trust , Frimley,United Kingdom - More than half of the total respondents were receiving long-term prophylaxis at the time of their most treated attack.
- 87% of respondents considered their attacks moderately severe to very severe.
- Those receiving parental on-demand treatment only and those receiving parental on-demand treatment plus LTP experienced substantial burden during their last treated HAE attack, in terms of physical, mental, and social QoL, as well as work productivity.
-
Phase 3 KONFIDENT Trial of Oral Sebetralstat for Treatment of Hereditary Angioedema Attacks: Analysis of the European and US Patient Subgroups:
Andrea Zanichelli , Operative Unit of Medicine, Angioedema Center, IRCCS Policlinico San Donato, San Donato Milanese,Milan, Italy ;Department of Biomedical Sciences for Health ,University of Milan ,Milan, Italy (Poster presentation)-
In the KONFIDENT phase 3 clinical trial, the positive efficacy and safety of sebetralstat as an on-demand treatment for HAE was consistent between the European and
U.S. subgroups.
-
In the KONFIDENT phase 3 clinical trial, the positive efficacy and safety of sebetralstat as an on-demand treatment for HAE was consistent between the European and
-
Patient-Reported Benefits of Early On-demand Treatment of HAE Attacks:
Mar Guilarte ,Allergy Department , Hospital Universitari Vall d'Hebron ,Barcelona, Spain - People living with HAE reported several positive benefits when treating attacks early with on-demand treatment: more likely than those who delayed treatment to carry their on-demand treatment with them, treat more attacks, feel less anxious when anticipating on-demand treatment, and recover more quickly from HAE attacks.
-
Treatment of HAE Attacks with Anticipated Future Oral On-demand Therapies as Reported by Patients: Anna Valerieva
Department of Allergology ,Medical University ofSofia ,Sofia, Bulgaria - According to a survey of more than 100 participants, people living with HAE who are using parenteral on-demand treatment may treat more of their attacks and treat earlier with the availability of an oral on-demand treatment option.
- In addition, respondents noted they are less likely to experience anxiety when anticipating administration of an oral on-demand treatment.
-
Global Frequency and Diagnosis of Hereditary Angioedema with Normal C1INH: A
Real World ACARE Survey :Markus Magerl ,Angioedema Center of Reference and Excellence (ACARE),Institute of Allergology , Charité – UniversitätsmedizinBerlin , corporate member of Freie UniversitätBerlin and Humboldt-Universität zuBerlin ,Berlin, Germany ;Fraunhofer Institute for Translational Medicine and Pharmacology ITMP , Immunology and Allergology,Berlin, Germany - Due to varying clinical approaches, there are substantial delays in diagnosis of HAE for people with normal C1INH, which currently has no standardized diagnostic pathway.
- There is a need for evolved and consistent approaches to improve accurate diagnosis and clinical management of this patient population.
Links to all posters and presentations can be found on the
In Memoriam:
About Sebetralstat
Discovered and developed entirely by the scientific team at
About Hereditary Angioedema
Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the location affected. All currently approved on-demand treatment options require either intravenous or subcutaneous administration.
About
For more information about
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241004668357/en/
Vice President, Corporate Affairs
(617) 448-0281
jsnyder@kalvista.com
Head, Investor Relations
(617) 771-5001
ryan.baker@kalvista.com
Source: